KLB
Beta-klotho
As of the edition of 20 October 2026, KLB (beta-klotho, UniProt Q86Z14) has 3 drugs tested at it and 4 companies on the list, 0 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q86Z14
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Solved structures
- 5
- Disease areas
- Digestive system; Nutrition and metabolism; Hormones; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 29
Drugs at this target
| Status | Count |
|---|---|
| Stopped | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Aldafermin | Stopped | Phase 3 | none listed |
| Pegbelfermin | Stopped | Phase 2 | none listed |
| Fazpilodemab | Stopped | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Undetermined | 4 |
| Total on the list | 4 |